DMAC Furnishes Press Release Detailing Q2 2025 Financial Results

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. announced its condensed consolidated financial results for the quarter ended June 30, 2025 and provided a business update via a press release attached as Exhibit 99.1 to this Form 8-K. The filing states the press release is furnished and incorporated by reference into Item 2.02, and expressly notes the information is not "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless specifically referenced. The company’s voting common shares trade on The Nasdaq Stock Market under the symbol DMAC. The 8-K lists Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page); the 8-K text itself contains no financial tables or line-item results, so readers must consult Exhibit 99.1 for detailed Q2 2025 figures and commentary.

Positive

• Press release furnished as Exhibit 99.1 announcing a business update and Q2 2025 condensed consolidated financial results
• Clear disclosure that the company’s common shares trade on The Nasdaq Stock Market under the symbol DMAC

Negative

• The 8-K text contains no financial figures or tables; detailed results are only available in Exhibit 99.1
• Information is furnished, not filed, meaning it is not "filed" for purposes of Section 18 of the Exchange Act and has limited incorporation into other filings

Insights

Financial Analyst

TL;DR Routine earnings press release furnished as Exhibit 99.1; the 8-K text contains no numeric results, so investors must read the exhibit for metrics.

The company used Item 2.02 to furnish a business update and condensed consolidated results for the quarter ended June 30, 2025. Because the press release is furnished rather than filed, the content is not subject to Section 18 liability protections and is not automatically incorporated into other SEC filings. The 8-K itself contains no financial tables or specific results in-line, so material numerical and ratio analysis cannot be performed from the filing text alone; those details will be in Exhibit 99.1.

Corporate Governance Expert

TL;DR Disclosure was furnished, not filed, limiting incorporation and Section 18 exposure while delivering the company’s Q2 2025 update to the market.

From a governance and disclosure control perspective, the company followed routine practice by furnishing a press release under Item 2.02 and including an Inline XBRL cover page as Exhibit 104. The explicit statement that the release is not "filed" means the content has narrower legal incorporation into other filings. The document confirms exchange listing information (Nasdaq, symbol DMAC) but provides no in-line financial statements; stakeholders should review Exhibit 99.1 for the substantive financial information and management commentary.

false 0001401040 0001401040 2025-08-12 2025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

DIAMEDICA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada	001-36291	Not Applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
301 Carlson Parkway, Suite 210 Minneapolis, Minnesota	55305
(Address of principal executive offices)	(Zip Code)

(763) 496-5454

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Voting common shares, no par value per share	DMAC	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.         Results of Operations and Financial Condition.

On August 12, 2025, DiaMedica Therapeutics Inc. (the “Company”) announced its condensed consolidated financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of Item 2.02 of this report.

The information contained in Item 2.02 of this report and Exhibit 99.1 to this report shall not be deemed to be “filed” with the United States Securities and Exchange Commission for purposes of Section 18 of the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference into any filings made by the Company under the United States Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.

Item 9.01         Financial Statements and Exhibits.

(d)         Exhibits.

	Exhibit No.		Description
	99.1		Press Release dated August 12, 2025 providing a business update and announcing second quarter 2025 financial results (furnished herewith)
	104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DIAMEDICA THERAPEUTICS INC.
	By:	/s/ Scott Kellen
		Scott Kellen
		Chief Financial Officer and Secretary

Dated: August 12, 2025

FAQ

What did DiaMedica (DMAC) report in this 8-K?

The company announced condensed consolidated financial results for the quarter ended June 30, 2025 and provided a business update via a press release furnished as Exhibit 99.1.

Where can I find the detailed Q2 2025 financial numbers for DMAC?

The 8-K attaches a press release as Exhibit 99.1 which provides the detailed Q2 2025 figures; the 8-K text itself contains no financial tables.

Is the press release in Exhibit 99.1 considered filed with the SEC?

No. The filing expressly states the press release is furnished and is not "filed" for purposes of Section 18 of the Exchange Act.

On which exchange do DiaMedica shares trade and what is the ticker?

DiaMedica’s voting common shares trade on The Nasdaq Stock Market under the symbol DMAC.

What exhibits are included with this 8-K?

Exhibit 99.1 is the press release providing a business update and Q2 2025 results, and Exhibit 104 is the Inline XBRL cover page.